| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FONC.2022.870396 |
| P2093 | author name string | Hanjiao Qin | |
| Jianfeng Zhong | |||
| Ge Zheng | |||
| Jiyao Sheng | |||
| Yien Xiang | |||
| P2860 | cites work | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae | Q24652685 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy | Q26826863 | ||
| Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors | Q27023623 | ||
| The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA | Q28297640 | ||
| Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo | Q28485252 | ||
| Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres | Q28541848 | ||
| CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA | Q29615786 | ||
| Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin | Q29617073 | ||
| Three-dimensional spheroid model in tumor biology | Q33679717 | ||
| Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma | Q34314916 | ||
| Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. | Q34896252 | ||
| HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma | Q91285728 | ||
| BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma | Q91447532 | ||
| Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture | Q91549436 | ||
| Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers? | Q91571320 | ||
| RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma | Q91866737 | ||
| The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy | Q91931497 | ||
| Potential tumor‑suppressive role of microRNA‑99a‑3p in sunitinib‑resistant renal cell carcinoma cells through the regulation of RRM2 | Q91998411 | ||
| The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma | Q92546197 | ||
| ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression | Q92675223 | ||
| Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma | Q92683914 | ||
| miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma | Q92722177 | ||
| Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma | Q93153864 | ||
| Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients | Q94587646 | ||
| Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant | Q94606253 | ||
| CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation | Q94937399 | ||
| Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study) | Q95936438 | ||
| Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma | Q96023037 | ||
| Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma | Q97533470 | ||
| Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma | Q97549596 | ||
| Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway | Q98464938 | ||
| Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma | Q98568586 | ||
| Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells | Q99235327 | ||
| LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation | Q99402566 | ||
| CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma | Q99616867 | ||
| Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma | Q100728131 | ||
| Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis | Q101117703 | ||
| Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance | Q101130204 | ||
| Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma | Q102133837 | ||
| Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma | Q104613583 | ||
| Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma | Q104788420 | ||
| Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells | Q107270365 | ||
| Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma | Q108003603 | ||
| Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC) | Q109715902 | ||
| Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways | Q110146996 | ||
| PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance | Q112289608 | ||
| Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma | Q112292253 | ||
| G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma | Q112294842 | ||
| Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway | Q112298224 | ||
| Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma | Q112713325 | ||
| Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib | Q38936109 | ||
| HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A. | Q38984146 | ||
| Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism | Q38991418 | ||
| Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells | Q39105266 | ||
| Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells | Q39142815 | ||
| Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib | Q39182553 | ||
| Expression of angiogenesis‐related gene profiles and development of resistance to tyrosine‐kinase inhibitor in advanced renal cell carcinoma: Characterization of sorafenib‐resistant cells derived from a cutaneous metastasis | Q39199929 | ||
| Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation | Q39213121 | ||
| A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance | Q39233612 | ||
| Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells | Q39349647 | ||
| Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model | Q39439657 | ||
| The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation | Q39530908 | ||
| Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma. | Q39798868 | ||
| Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. | Q39805218 | ||
| Drug and radiation resistance in spheroids: cell contact and kinetics | Q40630918 | ||
| Three-dimensional cell cultures: from molecular mechanisms to clinical applications | Q41633372 | ||
| Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma | Q41789122 | ||
| The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer | Q42044314 | ||
| Two mutations affecting conserved residues in the Met receptor operate via different mechanisms | Q42621322 | ||
| Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells | Q47124737 | ||
| EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming | Q47600932 | ||
| MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance | Q48230714 | ||
| Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. | Q48256655 | ||
| Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma | Q48729441 | ||
| Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells | Q49335182 | ||
| Corrigendum to "Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma" [Exp. Cell Res. (2017) 269-278]. | Q49642693 | ||
| Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. | Q50190222 | ||
| Hydrogels as extracellular matrix mimics for 3D cell culture. | Q34983262 | ||
| EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome | Q35000659 | ||
| Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications | Q35079536 | ||
| Three-dimensional cell culture: a breakthrough in vivo. | Q35381163 | ||
| Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation | Q35590169 | ||
| Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma | Q35675548 | ||
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. | Q35703000 | ||
| Comparative pO2 measurements in cell spheroids cultured with different techniques | Q36029142 | ||
| GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition | Q36069860 | ||
| Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. | Q36378883 | ||
| Activating mutations for the Met tyrosine kinase receptor in human cancer | Q36595980 | ||
| A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma | Q36606040 | ||
| Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux | Q36777194 | ||
| Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma | Q36868642 | ||
| Ovatodiolide Targetsβ-Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma | Q36916021 | ||
| Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge? | Q37024040 | ||
| Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. | Q37279290 | ||
| The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy | Q37576212 | ||
| Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma | Q37712156 | ||
| Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs | Q37745377 | ||
| Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity | Q38214357 | ||
| 3D cell culture systems: advantages and applications | Q38218818 | ||
| Microfluidic 3D cell culture: from tools to tissue models | Q38533196 | ||
| Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells. | Q38702055 | ||
| Three-dimensional cell culture models for anticancer drug screening: Worth the effort? | Q38724273 | ||
| MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model | Q38750187 | ||
| Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity. | Q38811667 | ||
| Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells | Q38817505 | ||
| CRISPR/Cas9 in Genome Editing and Beyond | Q38825624 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines | Q38840873 | ||
| A paper-based invasion assay: assessing chemotaxis of cancer cells in gradients of oxygen | Q38893793 | ||
| Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance | Q38924917 | ||
| Renal cancer. | Q50941188 | ||
| Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma | Q51328387 | ||
| Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal | Q52718768 | ||
| Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy. | Q52722792 | ||
| Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. | Q54291692 | ||
| The CRISPR tool kit for genome editing and beyond. | Q55233775 | ||
| Relations between pH, oxygen partial pressure and growth in cultured cell spheroids. | Q55485938 | ||
| Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models | Q56889140 | ||
| Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma | Q58693750 | ||
| miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma | Q58753441 | ||
| Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts | Q61797416 | ||
| Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma | Q64237817 | ||
| Size-dependent oxygenation and energy status in multicellular tumor spheroids | Q70295530 | ||
| Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma | Q89588623 | ||
| Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma | Q89635508 | ||
| Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma | Q89686088 | ||
| DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma | Q90169815 | ||
| Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance | Q90216421 | ||
| Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma | Q90326756 | ||
| Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma | Q90709698 | ||
| Potential new therapy of Rapalink-1, a new generation mTOR inhibitor, against sunitinib-resistant renal cell carcinoma | Q90787289 | ||
| EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation | Q91026376 | ||
| Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma | Q91229377 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P577 | publication date | 2022-05-10 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Advances in Renal Cell Carcinoma Drug Resistance Models | |
| P478 | volume | 12 |
Search more.